Solara Active Pharma Sciences Ltd. · NSE:SOLARA
Solara Active Pharma Sciences — Q3 FY2019 Earnings Presentation
31 slides from Solara Active Pharma Sciences's earnings presentation, Apr 16, 2019
Slide 1: Respect Integrity Transparency Efficiency - April 2019
RESPECT INTEGRITY TRANSPARENCY EFFICIENCY A P R I L 2 0 1 9
Slide 2: Solara is young but enterprising
a“ SOLARA Gur Solara is young but enterprising
Slide 3: Evolution on an experienced foundation
Evolution on an experienced foundation Demonstrated operational excellence over 2 decades • Demerged the select API business of Strides Shasun • Demerged Human API business from SeQuent to to integrate with human API business of SeQuent operate as Pure Play animal healthcare company • Expansion acro
Slide 4: Highlights
Highlights API business model with large scale infrastructure, wide products and established customer relationships Capabilities Research Complex chemistry capabilities including Pipeline of 20+ products under handling of catalytic hydrogenation, different stages of development hydride reductions, o
Slide 5: Building on Strong Core Values
Building on Strong Core Values Doing what is ‘RITE’ for the customers Respect Transparency We treat each other and our partners with Through timely communications, it is our endeavor to keep respect. We value and respect each others time. our stakeholders, suppliers and customers aware and well We w
Slide 6: Brief Profile of the Board of Directors
Brief Profile of the Board of Directors Deepak Vaidya Nirmal Bhogilal Non-Exec. Director & Chairman Independent Director Fellow member of the ICA in England and Chairman of the Batliboi Group. He was Wales. He has previously worked as the Past President and Committee Member of Country Head of Schrod
Slide 7: Solara's leadership team
Solara’s leadership team Leadership with several years of experience in the pharmaceutical industry Jitesh Devendra (Jitesh) CEO Jitesh has more than 20 years’ experience and has led the North America API business as well as managed the Formulations P&L business of erstwhile Shasun Pharmaceuticals L
Slide 8: Why a shift towards standalone API setup?
Why a shift towards standalone API setup? While the opportunity is growing, it needs a focused play USFDA’s increasing Supply chain IP conflicts and Increasing Pollution and oversight on APIs discontinuance competing interests Environmental Concerns • FDA’s increased oversight on • Regulatory requir
Slide 9: Strategically poised with integrated infrastructure
a“ SOLARA Yor * Strategically poised with integrated infrastructure
Slide 10: Robust manufacturing capabilities
Robust manufacturing capabilities 5 facilities with all major regulated market approvals Core focus • Mirrored facilities for developing products • Deploy systems that are highly automated and stringent, specifically in the labor intensive areas. • Focus on technology and production processes that r
Slide 11: Regulatory Approvals – Inspection Track Record
Regulatory Approvals – Inspection Track Record 11
Slide 12: Regulatory Approvals – Inspection Track Record
Regulatory Approvals – Inspection Track Record *As Mysore is an intermediate site, no regulatory inspection has been conducted so far. Site has a valid GMP certificate issued by the Drug Control Department, Government of Karnataka 12
Slide 13: Facilities
Facilities Pondicherry Facility ▪ The buildings for the manufacturing of Intermediates and isolation of final drug substance are separate. ▪ Packing sections are controlled and meets ISO Class - 8 requirements. ▪ Reactors are in the range of 1200 L to 12,500 L of size with MOC of SS, MSGL, GL ▪ High
Slide 14: Facilities
Facilities Multipurpose Mangalore Facility ▪ Multi purpose cGMP API and intermediate facility inspected by DCD, USFDA, WHO, EDQM, MFDS, TGA, AEMPS, ISO-14001 ▪ 6 Full fledged cleanrooms meeting ISO class-8 slandered can hand six products simultaneously ▪ Broad range of stainless steal and Mild steal
Slide 15: Dedicated research and development capabilities
Dedicated research and development capabilities Two India based R&D Centre for best in class product development Technical Expertise Strong technical leadership to develop high-quality pharma products that create strategic value for our partners and customers Product Selection Focus on differentiate
Slide 16: Wide product offerings and pipeline
Wide product offerings and pipeline Rich basket of niche high value products for the global markets DMF FILING RUN RATE GEOGRAPHY WISE FILINGS 9 78 11 8 6 6 17 08 FY16 FY17 FY18 FY19(P) • 50+ Commercial APIs predominantly in Anthelmintic, Anti-malarias, Anti-infective, Neuromuscular Insomnia, Anti P
Slide 17: Promising approach for CRAMS
Promising approach for CRAMS Confidentiality Responsiveness Performance Customer confidentiality Highly responsive, Delivery performance a KPI, 01 guaranteed 02 customer focused teams from inquiry to delivery 03 even at the proposal stage Team Transparency Feedback Dedicated Project High level of Po
Slide 18: Wide Service Offerings
Wide Service Offerings Commercial Pre-clinical Chemistry Phase I, II & III • Process • Synthesis & • Lead Synthesis • Process Optimization Validation Purification • Lead Optimization • cGMP Production • Capacities • Ref. Std. & Impurities • Cost Advantage Contract Development (FTEs) Lead Analogues,
Slide 19: R&D Capabilities in Synthetic Development
R&D Capabilities in Synthetic Development Polymer Chemistry Carbohydrate chemistry Inorganic chemistry Peptide chemistry Organometallic chemistry Multistep complex chiral molecules Enzymatic chemistry & Natural product synthesis 19
Slide 20: R&D Capabilities in Analytical Development
R&D Capabilities in Analytical Development Analytical method validation and method transfer as per ICH guidelines and FDA requirement for key starting materials, Intermediates & API Compliance Impurity profiling US FDA audited and approved analytical laboratory Impurity profiling and Quantification
Slide 21: Business development structure with customer centricity
Business development structure with customer centricity High focus on customer advocacy Business Development Team Core focus around portfolio strategy, selection, new opportunities and business analytics Go to market team Post the handover from BD team, GTM team focusses on business execution, drivi
Slide 22: EHS and Safety
EHS and Safety Zero Liquid Discharge System Biological Treatment Plant MEE ▪ Low TDS treatment followed by ▪ Biological Treatment Plant – LTDS & ▪ Multiple Effect Evaporation System Biological treatment system cum RO HTDS (MEE Plant) Plant. ▪ High TDS treatment followed by Pre Chemical treatment cum
Slide 23: Q3FY19 and 9MFY19 Performance
Q3FY19 and 9MFY19 PERFORMANCE. AN EVENTFUL YEAR FOR THE STRATEGIC GOALS 23
Slide 24: Key Highlights for the quarter
Key Highlights for the quarter “ Quarterly Update(QoQ) Quarterly Update(YoY) 9MFY19 Update(YoY) • Total Revenue was ₹3,601 Mn • Total Revenue was ₹3,601 Mn • Total Revenue was ₹10,071 for Q3FY19 as compared to for Q3FY19 as compared to Mn for 9MFY19 as compared We are pleased to report a stellar ₹3,
Slide 25: Key Business Highlights for the quarter
Key Business Highlights for the quarter Split by End- Base Business Geography » During Q3FY19, Base business grew by 3% over Q2FY19. North North » Growth in base business emanated from both ROW, America ROW, America , 36% , 37% volume and price. 24% 23% » Top 10 Customer account for 55% revenues whi
Slide 26: Q3FY19 Performance - QoQ
Q3FY19 Performance - QoQ Financial Highlights Quarterly Trend Particulars Q3 FY19 Q2 FY19 QoQ Revenues Operating EBITDA Reported EBITDA Revenue 3,601 3,437 5% 3,601 3,437 Operating EBITDA 757 669 13% OP EBITDA Margins 21.0% 19.5% 150 bps R&D Cost -104 -111 757 656 669 Forex gain/(Loss) 3 -64 494 Rep
Slide 27: Q3FY19 Performance - YoY
Q3FY19 Performance- YoY Financial Quarterly Trend Highlights Particulars Q3 FY19 Q3 FY18 YoY Revenues Operating EBITDA Reported EBITDA Revenue 3,601 2,361 53% 3,601 Operating EBITDA 757 235 222% 2,361 1100 OP EBITDA Margins 21.0% 10.0% bps R&D Cost -104 -53 757 656 235 229 Forex gain/(Loss) 3 47 Rep
Slide 28: 9MFY19 Review
9MFY19 Review Financial Highlights 9M Trend Particulars 9MFY19 9MFY18 Change Revenues Operating EBITDA Reported EBITDA Revenue 10,071 7,498 34% 2,057 1,066 93% 10,071 Operating EBITDA OP EBITDA Margins 20.4% 14.2% 620 bps 7,498 R&D Cost -312 -75 Forex gain/(Loss) -129 49 Reported EBITDA 1,615 1,040
Slide 29: Corporate Update
Corporate Update “ Key Updates » The board of directors at their meeting held today also approved an aggregate fundraising of ₹4,600 Mn over a period of 18 months from the Promoters’ Group and TPG Growth IV SF Pte. Ltd. (TPG Growth ) through allotment of The proposed investment by TPG, a leading con
Slide 30: 5 years perspective
5 years perspective Business Continuity Portfolio of new products and new customers to augment current base and enable steady growth Worldwide Presence Established strongholds in key regulated markets and growth territories Well on its path to become a leading pure- play API company with focus on hi
Slide 31: Registered Office
REGISTERED OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703. Tel.: +91 22 2789 2924 Fax No. +91 22 2789 2942 Email: investors@solara.co.in Website: www.solara.co.in CIN: U24230MH2017PLC291636 CORPORATE OFFICE 3rd & 4th Floor, Batra Centre, No.28, Sardar Patel Road, Guindy, Chennai - 60
Solara Active Pharma Sciences — Q3 FY2019 Earnings Presentation on 6ix